




Metabolic perturbations prior to hepatocellular carcinoma diagnosis - Findings from a
prospective observational cohort study
Stepien, Magdalena; Keski-Rahkonen, Pekka; Kiss, Agneta; Robinot, Nivonirina; Duarte-
Salles, Talita; Murphy, Neil; Perlemuter, Gabriel; Viallon, Vivian; Tjønneland, Anne;
Rostgaard-Hansen, Agnetha Linn; Dahm, Christina C; Overvad, Kim; Boutron-Ruault, Marie-
Christine; Mancini, Francesca Romana; Mahamat-Saleh, Yahya; Aleksandrova, Krasimira;
Kaaks, Rudolf; Kühn, Tilman; Trichopoulou, Antonia; Karakatsani, Anna; Panico, Salvatore;
Tumino, Rosario; Palli, Domenico; Tagliabue, Giovanna; Naccarati, Alessio; Vermeulen, Roel
C H; Bueno-de-Mesquita, H Bas; Weiderpass, Elisabete; Skeie, Guri; Ramón Quirós, J;
Ardanaz, Eva; Mokoroa, Olatz; Sala, Núria; Sánchez, Maria-Jose; Huerta, José María;
Winkvist, Anna; Harlid, Sophia; Ohlsson, Bodil; Sjöberg, Klas; Schmidt, Julie A; Wareham,
Nick; Khaw, Kay-Tee; Ferrari, Pietro; Rothwell, Joseph A; Gunter, Marc; Riboli, Elio; Scalbert,
Augustin; Jenab, Mazda
Published in:
International Journal of Cancer





Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/ijc.33236 
 
Metabolic perturbations prior to hepatocellular carcinoma diagnosis – Findings 
from a prospective observational cohort study 
Magdalena Stepien1*, Pekka Keski-Rahkonen1*, Agneta Kiss1, Nivonirina Robinot1, 
Talita Duarte-Salles1,2, Neil Murphy1, Gabriel Perlemuter3,4,5, Vivian Viallon1, Anne 
Tjønneland6, Agnetha Linn Rostgaard-Hansen6, Christina C. Dahm7, Kim Overvad7,8, 
Marie-Christine Boutron-Ruault9,10, Francesca Romana Mancini9,10, Yahya Mahamat-
Saleh9,10, Krasimira Aleksandrova11, Rudolf Kaaks12, Tilman Kühn12, Antonia 
Trichopoulou13,14, Anna Karakatsani13,15, Salvatore Panico16, Rosario Tumino17, 
Domenico Palli18, Giovanna Tagliabue19, Alessio Naccarati20, Roel C.H. Vermeulen21, 
H. Bas Bueno-de-Mesquita22,23,24,25, Elisabete Weiderpass1, Guri Skeie26, J. Ramón 
Quirós27, Eva Ardanaz28,29,30, Olatz Mokoroa30,31, Núria Sala32, Maria-Jose 
Sánchez30,33, José María Huerta30,34, Anna Winkvist35,36, Sophia Harlid37, Bodil 
Ohlsson38, Klas Sjöberg39, Julie A Schmidt40, Nick Wareham41, Kay-Tee Khaw42, 
Pietro Ferrari1, Joseph A. Rothwell1,10, Marc Gunter1, Elio Riboli24, and Augustin 
Scalbert1҂, Mazda Jenab1҂ 
* These authors contributed equally to this project 
҂ These authors contributed equally to this project 
1. International Agency for Research on Cancer (IARC-WHO), Lyon, France. 
2. Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), 
Barcelona, Spain. 
3. INSERM UMRS U996 – Intestinal Microbiota, Macrophages and Liver Inflammation, 
DHU Hepatinov, Clamart, France. 
This article is protected by copyright. All rights reserved.
 
 
4. Université Paris-Sud, Paris-Saclay, Clamart, France. 
5. AP-HP, Hepato-gastroenterology and Nutrition, Antoine-Béclère Hospital, Clamart, 
France. 
6. Diet, Genes and Environment Unit, Danish Cancer Society Research Center, 
Copenhagen, Denmark 
7. Section for Epidemiology, Department of Public Health, Aarhus University, Denmark. 
8. Department of Cardiology, Aalborg University Hospital, Denmark. 
9. CESP, Faculté de médecine - Université Paris-Sud, Faculté de médecine - UVSQ, 
INSERM, Université Paris-Saclay, Villejuif, France. 
10. Institut Gustave Roussy, Villejuif, France. 
11. Department of Epidemiology, German Institute of Human Nutrition, Potsdam-
Rehbrücke, Germany. 
12. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
Heidelberg, Germany. 
13. Hellenic Health Foundation, Athens, Greece. 
14. WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology 
and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, 
School of Medicine, National and Kapodistrian University of Athens, Greece. 
15. Second Pulmonary Medicine Department, School of Medicine, National and 
Kapodistrian University of Athens, “ATTIKON” University Hospital, Haidari, Greece. 
16. Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. 
17. Cancer Registry and Histopathology Department, Provincial Health Authority (ASP) 
Ragusa, Italy. 
This article is protected by copyright. All rights reserved.
 
 
18. Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and 
Prevention Institute (ISPO), Florence, Italy. 
19. Lombardy Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 
Milano, Italy 
20. Molecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM) 
Torino, Torino, Italy 
21. Institute of Risk Assessment Sciences, Utrecht University, The Netherlands. 
22. Department for Determinants of Chronic Diseases (DCD), National Institute for Public 
Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands. 
23. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, 
The Netherlands. 
24. Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
College London, London, United Kingdom. 
25. Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, 
Pantai Valley, Kuala Lumpur, Malaysia. 
26. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, 
The Arctic University of Norway, Tromsø, Norway. 
27. Public Health Directorate, Asturias, Spain. 
28. Navarra Public Health Institute, Pamplona, Spain. 
29. IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. 
30. CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain. 
31. Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, 
Spain. 
This article is protected by copyright. All rights reserved.
 
 
32. Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program 
and Translational Research Laboratory, Catalan Institute of Oncology (IDIBELL), 
Barcelona, Spain. 
33. Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs. 
Granada. Hospitales Universitarios de Granada/Universidad de Granada, Granada, 
Spain. 
34. Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, 
Spain. 
35. The Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden  
36. Department of Public Health and Clinical Medicine, Nutrition Research, Umeå 
University, Umeå, Sweden 
37. Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. 
38. Skåne University Hospital, Department of Internal Medicine, Lund University, Malmö, 
Sweden. 
39. Skåne University Hospital, Department of Gastroenterology and Nutrition, Lund 
University, Malmö, Sweden. 
40. Cancer Epidemiology Unit, Nuffield Department of Population Health, University of 
Oxford, Oxford, United Kingdom. 
41. MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom. 
42. University of Cambridge, School of Clinical Medicine, Clinical Gerontology Unit, 
Addenbrooke’s Hospital, Cambridge, United Kingdom. 
Corresponding authors:  
Dr. Mazda Jenab, email: jenabm@iarc.fr Twitter: @Mazda_J and Dr. Augustin 
Scalbert, email; scalberta@iarc.fr  
This article is protected by copyright. All rights reserved.
 
 
IARC-WHO, 150 Cours Albert Thomas, Lyon, 69008 
 
List of abbreviations: 
ALP, liver-specific alkaline phosphatase  
ALT, alanine aminotransferase;  
AST, aspartate aminotransferase ;  
BMI, body mass index;  
DHEA-S,  dehydroepiandrosterone sulfate;  
EPIC, European Prospective Investigation into Cancer and Nutrition cohort;  
GGT,  gamma-glutamyltransferase ;  
HCC, hepatocellular carcinoma;  
HILIC, hydrophilic interaction chromatography;  
HPLA, p-hydroxyphenyllactic acid;  
lysoPC, lysophosphatidylcholine;  
MS, mass spectrometry; 
NMR, magnetic resonance spectroscopy;  
OR, odds ratio;  
PC, phosphatidylcholines;  
ROC, Receiver Operation Characteristics curve;  
RP, reversed phase chromatography;  
SD, standard deviation;  
γ-CEHC , γ-carboxyethyl hydroxychroman. 




Novelty and Impact:  
The aim of this study was to gain insight into metabolic perturbations underlying the 
development of hepatocellular carcinoma using detailed data from a large, 
multinational prospective observational cohort. High resolution mass spectrometry-
based metabolomics was conducted on blood samples collected pre-diagnostically 
upon recruitment into the cohort. Cases were identified upon follow-up and compared 
to matched controls. We controlled for known aetiologies (hepatitis infection, heavy 
alcohol intake, smoking) and major confounding factors, such as obesity. Alterations 
were observed in a wide range of metabolites related to exogenous and mutagenic 
exposures, liver dysfunction and bile acid/phospholipid metabolism, providing insight 
into early metabolic perturbations and mechanisms leading to this deadly cancer.  
 
Abstract  
Hepatocellular carcinoma (HCC) development entails changes in liver metabolism. 
Current knowledge on metabolic perturbations in HCC is derived mostly from case-
control designs, with sparse information from prospective cohorts. Our objective was 
to apply comprehensive metabolite profiling to detect metabolites whose serum 
concentrations are associated with HCC development, using biological samples from 
within the prospective EPIC cohort (>520,000 participants, ), where we identified 129 
HCC cases matched 1:1 to controls. We conducted high resolution untargeted liquid 
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chromatography-mass spectrometry based metabolomics on serum samples 
collected at recruitment prior to cancer diagnosis. Multivariable conditional logistic 
regression was applied controlling for dietary habits, alcohol consumption, smoking, 
body size, hepatitis infection and liver dysfunction. Corrections for multiple 
comparisons were applied. Of 9,206 molecular features detected, 220 discriminated 
HCC cases from controls. Detailed feature annotation revealed 92 metabolites 
associated with HCC risk; 14 of which were unambiguously identified using pure 
reference standards. Positive HCC risk associations were observed for N1-
acetylspermidine, isatin, p-hydroxyphenyllactic acid, tyrosine, sphingosine, L,L-
cyclo(leucylprolyl), glycochenodeoxycholic acid, glycocholic acid, and 7-
methylguanine. Inverse risk associations were observed for retinol, 
dehydroepiandrosterone sulfate, glycerophosphocholine, γ-carboxyethyl 
hydroxychroman, and creatine. Discernible differences for these metabolites were 
observed between cases and controls up to 10 years prior to diagnosis. Our 
observations highlight the diversity of metabolic perturbations involved in HCC 
development and replicate previous observations (metabolism of bile acids, amino 
acids, phospholipids) made in Asian and Scandinavian populations. These findings 
emphasize the role of metabolic pathways associated with steroid metabolism and 
immunity and specific dietary and environmental exposures in HCC development.    
Keywords: hepatocellular carcinoma; untargeted metabolomics; prospective 
observational cohort;  
Introduction 
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Primary liver cancer is the second most common cause of death from cancer 
worldwide (1). Established risk factors for hepatocellular carcinoma (HCC), the major 
histology of primary liver cancers, are chronic hepatitis infection, aflatoxin exposure, 
smoking and alcohol abuse (2), but obesity, diabetes and unhealthy dietary and 
lifestyle habits are also becoming increasingly recognized as important HCC risk 
factors, particularly in regions where hepatitis infection and aflatoxin exposures are 
less predominant (3). HCC are often diagnosed at late stages and have limited 
treatment options, which is worrisome owing to the growing incidence of this highly 
fatal disease in many populations (4). It has been suggested that high obesity and 
diabetes rates in some populations are major contributors to the observed incidence 
rate increases (5). Most HCC are considered to develop within a background of 
inflammation, liver damage and cirrhosis. However, a sizeable proportion is thought 
to develop in the absence of underlying cirrhosis, hence escaping traditional clinical 
surveillance particularly in populations with lower prevalence of hepatitis infection 
and alcohol abuse, and higher prevalence of metabolic syndrome and non-alcoholic 
fatty liver disease (NAFLD) which are largely obesity-related (6;7). Obesity may also 
impair the detection of cirrhosis or HCC by reducing the sensitivity of abdominal 
ultrasound, a primary tool for HCC surveillance in high risk populations (8). Thus, 
effective HCC control will need to rely on strategies for both primary prevention and 
early detection, necessitating additional research into HCC etiology.  
Decreased liver functionality is considered an early event in liver cancer development 
and given the central metabolic role of the liver various metabolic perturbations are 
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very likely to be observed in blood. In addition, circulating biomarkers indicative of 
various lifestyle or environmental exposures that may affect HCC risk are also likely 
observable (9).  Such metabolic signatures can be identified via various metabolomic 
techniques, such as those based on high resolution liquid chromatography mass 
spectrometry (LC-MS), which may be applied to blood samples to observe a broad 
spectrum of low-molecular-weight compounds which may be reflective of various 
exogenous exposures and associated with normal endogenous processes or 
perturbed metabolic functionality. In fact, several animal and human studies have 
already shown that metabolomics can provide novel insights into pathological 
processes during development of various liver diseases (10;11), and provide 
potentially novel diagnostic biomarkers of HCC for screening in high risk populations 
(12-14). Most of the studies that have applied metabolic profiling in HCC have been 
either based on case-control designs, or conducted on high risk patient groups (e.g. 
viral hepatitis, cirrhosis or other chronic liver diseases), or in populations where more 
traditional HCC risk factors predominate (15). However, comparatively very little 
information is available from prospective, observational cohorts about possible 
metabolic alterations related to HCC development, particularly from European or 
Western populations (16-18). Information derived from prospective observational 
cohorts is important because data and biological samples have been collected from 
healthy participants before diagnosis, thus reducing the biases of recall and reverse 
causality and allowing considerable insight into the complex processes of cancer 
development. For example, within the European Prospective Investigation on Cancer 
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and Nutrition (EPIC) cohort, a number of targeted metabolomic studies (i.e. the 
measurement of defined groups of characterized and annotated metabolites; about 
150 metabolites measured) have been conducted to assess metabolite patterns 
associated with risk of several cancers such as the breast (19) and prostate (20;21), 
as well as with various lifestyle factors, such as body mass index (22) and select 
dietary components (23). They have revealed important insights on development 
processes and exogenous exposures associated with these cancers. Similar 
metabolomics techniques have also been applied in other prospective studies to 
explore cancer development at various anatomical sites, including HCC (18;24-26). 
We have also previously conducted two other metabolomics studies on HCC risk 
factors in the EPIC cohort using nuclear magnetic resonance spectroscopy (NMR) 
(17) and a targeted kit-based LC-MS assay (16). We observed alterations in amino 
acid, lipid and carbohydrate metabolism associated with HCC development, but our 
findings provided little new insight into HCC etiology or specific environmental 
exposures potentially linked to HCC development, due in large part to the low 
sensitivity of NMR (17) and the limited number of metabolites measured with the kit-
based assay (16).  
In the present study, our objective was to delve more deeply into an exploration of 
metabolic perturbations in HCC development through application of untargeted 
metabolomics (i.e. the comprehensive analysis of all measurable analytes, but 
requiring intensive efforts towards metabolite annotation) using a highly sensitive LC-
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MS technique able to detect thousands of metabolites in typical blood samples (27) 
using a case-control design nested within the prospective EPIC cohort.  
Materials and methods 
Study design  
The rationale and study design of the large multi-center prospective, observational 
EPIC cohort have been previously described (28). Briefly, between 1991 and 2000 
more than 520,000 apparently healthy men and women aged 20-85 years were 
recruited in 23 centers throughout 10 countries (Denmark, France, Germany, 
Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom). At 
recruitment, standardized dietary, lifestyle and socio-demographic questionnaires, 
blood samples and anthropometric measurements were collected from most 
participants (29). Blood samples are stored at the International Agency for Research 
on Cancer (IARC-WHO, Lyon, France) in -196°C liquid nitrogen for all countries 
except Denmark (-150°C, nitrogen vapour) and Sweden (-80°C, freezers), where 
they are stored locally.  
Nested Case-Control Study  
From 477,206 eligible participants, we included 129 HCC cases (diagnosed post-
recruitment into the cohort and identified up to December 2010) with available 
baseline (i.e. pre-diagnostic) blood samples. The cases were followed-up for a 
median of 6.2 years / mean of 5.9 years from baseline recruitment until HCC 
diagnosis. For each case, we selected one control (n=129) by incidence density 
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sampling from all eligible cohort participants alive and matched by age at blood 
collection (±1 year), sex, study center, time of the day at blood collection (±3 hours), 
fasting status at blood collection (<3, 3-6,and >6 hours); and additionally among 
women by menopausal status (pre-, peri-, and postmenopausal), and hormone 
replacement therapy use at time of blood collection (yes/no). Incidence density 
sampling for control selection is a common method of choice for unbiased results in 
case-control studies nested within a prospective cohort (30). The method involves 
matching each case to a sample of those who are at risk from within the cohort 
population at the time of case occurrence. 
HCC was defined as C22.0 according to the 10th revision of the International 
Statistical Classification of Diseases, Injury and Causes of Death (ICD10),  with 
morphology codes “8170/3” or “8180/3” according to the 2nd edition of the 
International Classification of Diseases for Oncology (ICD-O-2). For each case 
identified, the histology and diagnostic methods were reviewed by a trained 
pathologist to exclude metastatic cases or other types of primary liver cancers. 
Details on participant exclusion criteria and cancer incidence determination are 
described in the Supplementary Materials and Methods. 
Untargeted Metabolomics  
Detailed methods for the metabolomics analyses (i.e. sample preparation and 
analysis. data preprocessing, and feature identification) are provided in the 
Supplementary Materials and Methods. Briefly, samples were analysed with a 
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UHPLC-QTOF-MS system (Agilent Technologies, Santa Clara, CA, USA) using four 
different analytical configurations with reversed phase (RP) or hydrophilic interaction 
chromatography (HILIC) columns and positive or negative MS ionization modes (i.e. 
RP +/-, HILIC +/). Peak areas were used as a measurement of feature intensity. For 
identification, mass to charge rations (m/z) were searched against the Human 
Metabolome Database (31) and METLIN (32), using ions [M+H]+, [M+Na]+, [M-H]-, 
[M+FA-H]-, with 8 ppm molecular weight tolerance. Where pure chemical standards 
were commercially available, identification was confirmed by reanalysis of 
representative samples and pure chemical standards comparing retention times and 
MS/MS spectra. When standards were not available, MS/MS spectra were acquired 
when possible and compared against those in mzCloud (www.mzcloud.org) or 
METLIN. Level of identification was determined as proposed by Sumner et al (33) in 
line with recommendations of the Metabolomics Standards Initiative which ranks 
metabolites into 4 distinct categories: unambiguous identification using pure 
standards (Level 1), identified with a high level of confidence based on chemical 
features and characteristics (Level 2), identified to a known chemical class (Level 3) 
and unknown / unidentifiable compounds (Level 4). For the purposes of this analysis, 
Levels 1-3 are considered identified metabolites, but with varying levels of certainty 
(i.e. unambiguous, highly likely and chemical class only).  
Additional Laboratory Measures 
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In a large subset of subjects, a score of liver function (indicator of underlying liver 
damage) was computed using additional and already available biomarker measures 
(34;35) (details in Table 1 footnotes). 
Dataset preparation and statistical analyses 
A separate analysis was conducted for each dataset from the four analytical 
configurations (i.e. RP +/-, HILIC +/-). In each dataset, features missing from more 
than25% of all samples were excluded to avoid extensive imputation of the data 
before the paired statistical analysis (see Figure 1 for details). In order to retain a 
maximum number of complete case-control sets in the statistical analyses, missing 
values for any feature (features not detected in a given subject) for any feature were 
replaced with the minimum intensity of that feature in the dataset (Figure 1). To 
assess differences between cases and controls, feature intensities were log2-
transformed (to improve data normality) and z-standardized (to better enable 
comparisons across a wide intensity range), and subsequently entered into 
conditional logistic regression models from which odds ratios (OR) and 95% 
confidence intervals (95% CI) were computed. Two main statistical models were 
applied, (a) a crude model, conditioned on the matching criteria only and (b) a 
detailed multivariable model with additional adjustments for continuous variables 
body mass index (BMI, kg/m2), waist circumference (cm), recreational and household 
physical activity (Met-hours/week), alcohol intake at recruitment (g/d), and categories 
of lifetime alcohol intake pattern, smoking status and highest level of education 
attainment (for categories see Table 1). The Benjamini-Hochberg correction for 
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multiple testing was applied using the multi-test procedure in SAS and a q-value of 
≤0.05 was considered as statistically significant. Additionally, fold change between 
the median intensity for the cases vs. the controls was used to rank the features by 
their absolute intensity difference. Thresholds for the selection of the most 
discriminating features for annotation were based on absolute median fold change of 
≥1.20. Additional adjustments for hepatitis infection status (to correct for this 
established risk factor), self-reported type-2 diabetes at baseline (to correct for 
potential influence of diabetes-related metabolic dysfunction) and a composite score 
of liver function (to correct for the extent of liver dysfunctionality and capacity) were 
applied in supplementary analyses for all identified features.  
Sensitivity analyses were conducted excluding first 2 and 4 years of follow-up (n=22 
and n=43 cases excluded, respectively) to assess potential reverse causation. For 
these analyses, a p-value ≤0.05 was considered statistically significant.  
Pearson correlation coefficients were used to assess the correlations between 
metabolites that were annotated (i.e. those at Levels of identification 1-3(33), but not 
unknown metabolites). For these same annotated metabolites, we conducted 
principal component analyses in order to illustrate the separation of profiles from 
baseline over the timeline of the follow-up period (i.e. from baseline recruitment into 
the cohort to the date of diagnosis) between identified features of cases and controls. 
In addition, we then constructed a Receiver Operating Characteristics (ROC) curve 
based on stepwise forward selection of metabolites from the panel of metabolites that 
were annotated to Level 1 (i.e. the panel of metabolites that were significantly 
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different between cases and controls and unambiguously identified using a pure 
standard) and those at Levels 1-3 (33). The final areas under the ROC curve for the 
identified discriminant features were obtained using leave-one-out cross validation. 
All statistical tests were two-sided. Analyses were conducted using SAS version 9.3 
(SAS Institute, Cary, NC), R version 3.4.3 (Principal Component Analyses) or 
MetaboAnalyst version 4.0 (Heatmap). 
Results 
Characteristics of the HCC cases and their matched controls are presented in Table 
1. Cases were primarily men, former drinkers and current smokers, and had higher 
waist circumference, higher prevalence of hepatitis B/C infection, and higher degree 
of liver dysfunction than matched controls. The average length of follow-up was 8.5 
years for cases and controls combined and 5.9 years for cases alone, with a 
maximum follow-up length of 15 years from baseline.   
From the combined total of 9,206 molecular features provided by the four analytical 
configurations of the LC-MS, 5,229 (i.e. 2551 (RP+), 1178 (RP-), 736 (HILIC+) and 
764 (HILIC-)) were present in at least 75% of all samples and were exported for 
statistical analyses (Figure 1). Initially, 333 (RP+), 20 (RP-), 68 (HILIC+) and 14 
(HILIC-) features were found to be statistically significantly associated with HCC risk 
in multivariable models (Supplementary Tables 1A, 1B, 1C and 1D, respectively). 
Excluding the features with a median fold change less than 1.20 resulted in a total of 
220 features from the 4 analytical configurations combined. From these 220 features, 
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114 individual compounds (i.e. confirmed molecules that consisted of one or more 
features) were observed in the four datasets (Figure 1) and are visualized in volcano 
plots (Supplementary Figure 1).  
Of the 114 individual compounds, 22 were also detected by at least one of the other 
three profiling configurations, leaving a total of 92 unique annotated compounds. 
Each profiling configuration identified at least 5 unique compounds, highlighting the 
advantages of applying all four orthogonal analytical configurations for more 
comprehensive metabolite coverage. Identification was attempted for each of these 
92 unique compounds, ranking them according to varying levels of confidence based 
on the recommendations of the Metabolomics Standards Initiative (33). Fourteen 
metabolites were unambiguously identified using pure reference standards (Level1, 
Table 2), another 23 compounds were identified with a high level of confidence 
based on chemical features and characteristics (Level 2, Table 3) and 9 compounds 
were identified to a known chemical class (Level 3, Table 4), summing to a total of 46 
identified metabolites. Pearson correlation coefficients between these 46 identified 
metabolites are shown in Supplementary Figure 2. The remaining 46 metabolites 
could not be identified and are listed as unknown (Level 4, Table 4). Intensity means, 
standard deviation and medians for these 92 compounds are shown in 
Supplementary Table 2A. 
The multivariable adjusted HCC risk associations for the 14 metabolites identified at 
Level 1 are shown in Table 2. Of these 14 metabolites, 5 were inversely associated 
with HCC risk (q-value ≤0.05): retinol (OR=0.27, 95%CI: 0.16-0.48), 
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dehydroepiandrosterone sulfate (DHEA-S; OR=0.35, 95%CI: 0.22-0.57), 
glycerophosphocholine (OR=0.44, 95%CI: 0.28-0.71), γ-carboxyethyl 
hydroxychroman (γ-CEHC; OR=0.56, 95%CI: 0.39-0.81), creatine (OR=0.56, 95%CI: 
0.37-0.83). The remaining 9 metabolites were positively associated with HCC risk: 
N1-acetylspermidine (OR=2.16, 95%CI: 1.38-3.37), isatin (OR=2.56, 95%CI: 1.53-
4.29), p-hydroxyphenyllactic acid (HPLA; OR=2.63, 95%CI: 1.62-4.28), tyrosine 
(OR=2.77, 95%CI: 1.58-4.83), sphingosine (OR=2.79, 95%CI: 1.66-4.71), L,L-
cyclo(leucylprolyl) (OR=3.25, 95%CI: 1.91-5.53), glycochenodeoxycholic acid 
(OR=3.31, 95%CI: 1.99-5.51), glycocholic acid (OR=4.07, 95%CI: 2.32-7.14), and 7-
methylguanine (OR=6.78, 95%CI: 3.24-14.18).  
We additionally conducted ROC discriminant analyses from the panel of the 14 Level 
1 identified metabolites. The analyses showed that the discrimination between cases 
and controls was largely driven by retinol, DHEA-s, LL-cycloleucylpropyl and 7-
methylguanine. Additional ROC analysis using leave-one-out cross validation for 
these 4 independent metabolites indicated a 84.6% discriminatory accuracy, 
compared to a 85.0% discriminatory accuracy when all 14 Level 1 identified 
metabolites were modelled. This method of validation was chosen to avoid likely 
statistical power issues that would arise from splitting the main dataset into discovery 
and validation sub-sets, each of which would include a smaller number of cases. 
Conversely, we applied the leave-one-out cross validation approach to the identified 
metabolites rather than at the stage of feature selection, as would be the case in a 
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true validation setting with training and validation sub-sets. Thus, the AUC estimate is 
likely to be biased. 
Multivariable-adjusted HCC risk associations for the twenty-three Level 2 metabolites 
(largely phosphatidylcholines (PC), lysophosphatidylcholines (lysoPC) of various 
chain lengths, diacylglycerols, two bilirubin metabolites and benzoylcarnitine) are 
shown in Table 3. Multivariable-adjusted HCC risk associations for Level 3 (some 
glycerophosphocholines and C19 steroid sulfates) and Level 4 compounds are 
shown in Table 4.  
Results for the crude models conditioned on the matching criteria only are shown in 
Supplementary Table 2B. Supplementary analyses with additional adjustments for 
hepatitis B and/or C infection status, self-reported diabetes status at baseline 
(Supplementary Table 2C), and a score of liver functionality within the multivariable 
analysis model did not materially alter the findings (Supplementary Table 2D). In 
sensitivity analyses, the observed associations, particularly for Level 1 and Level 2 
compounds were unaltered after exclusion of case-control pairs where the case 
participant was diagnosed within either the first 2 or 4 years of follow-up 
(Supplementary Table 2E).  
We conducted two principal component analyses, one based on the 46 metabolites 
identified to Levels 1-3 as well as a second one restricted to the 14 metabolites 
identified to Level 1 (Figure 2). These analyses show distinct differences between 
metabolic profiles of HCC cases compared to control participants, up to 10 years 
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prior to diagnosis. Additional sensitivity analyses excluding case-control pairs where 
the case was diagnosed within the first 4 years of enrolment into the cohort did not 
alter the clear distinction in metabolite profiles between HCC cases versus controls 
(Figure 2).  
Detailed information on metabolite identification with chromatograms and spectra is 
provided in Supplementary Materials (Identification of Metabolites). 
Discussion 
In this case-control study nested within a large, multinational observational 
prospective cohort, we applied a powerful MS-based untargeted metabolomics 
approach to explore metabolic perturbations underlying HCC development. The 
cases in our observational cohort were enrolled at the baseline period (i.e. data and 
blood samples collected upon recruitment) when the participants where under 
apparent health. Later, at various time points post-recruitment, some of the cohort 
participants were diagnosed with HCC. Thus, the cases in our study originate from 
different time points after baseline recruitment. In the sub-group of cases who were 
diagnosed closer to baseline, it is likely that the processes of HCC were already 
underway even though undiagnosed, possibly within a background of other liver 
pathologies. However, in the sub-group of subjects where the HCC was diagnosed 
later on during the cohort follow-up, the baseline blood samples are likely to have 
been collected in the absence of HCC or at its earlier stages. Due to the liver’s 
central metabolic roles, it is thought that metabolic disturbances are early events in 
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the development of chronic liver diseases and HCC (36). This premise underscores 
the rationale behind our study, conducted within the setting of an observational 
prospective cohort. We were able to determine 92 distinct metabolites whose relative 
concentrations were different between HCC cases and their matched controls in pre-
diagnostic blood samples. Of these 92 compounds, we were able to identify 46 of 
which 14 were unambiguous (Level 1 (33)) and an additional 23 and 9 with high 
degrees of confidence (Levels 2 and 3, respectively (33)). We show, using principle 
component analyses, that the differences between HCC cases and controls are 
apparent as far back as 10 years prior to diagnosis, even with exclusion of cases 
diagnosed within the first 2 or 4 years of follow-up. We observed perturbations in 
general classes of metabolites, such as amino acids and bile acids, but also in 
xenobiotics as indicators of lifestyle exposures, as well as some compounds with 
purported roles in immune function, hormone metabolism, gut microbiome activity 
and liver fat content - underscoring the complexity of metabolic disturbances in HCC 
development. The metabolites identified may be involved directly and/or be markers 
of various exposures associated with cancer risk. Moreover, we accounted for 
established etiologies of HCC such as hepatitis infection, high alcohol consumption 
and smoking in our statistical analysis models. Our observations were mostly 
unchanged with these adjustments, suggesting that metabolic perturbations in HCC 
may be largely similar, irrespective of the main underlying etiology of the tumor.  
Of the 46 metabolites that we could identify in this study, 14 were confirmed using 
authentic chemical standards. Several of these appear to be related to dietary and 
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lifestyle habits. Specifically, we observed inverse HCC risk associations for retinol 
(biologically active form of vitamin A) and γ-CEHC (a product of liver metabolism of γ-
tocopherol) (37;38). Retinol has a plausible role in liver carcinogenesis (e.g. 
modulation of immune function, cell growth (39)). Its potential association with liver 
cancer has been previously assessed in two prospective studies, a Finnish cohort of 
male smokers (40) as well as a cohort of Chinese men (41) both of whose findings 
are in line with our own observations. γ-CEHC shows some antioxidant and anti-
inflammatory properties, similar to γ-tocopherol (38;42). It has been purported as a 
treatment of non-alcoholic steatohepatitis, a precursor of liver cirrhosis and risk factor 
for HCC development (43), but little other data is available on any specific HCC 
protective roles for this compound.  
We also observed inverse HCC risk associations for glycerophosphocholine, several 
lysoPCs, creatine and DHEA-S, a steroid hormone. Interestingly, decreased 
glycerophosphocholine level has been observed to be predictive of higher circulating 
vitamin D concentrations (44), which would be in line with our earlier observation of a 
strong inverse HCC risk association with higher circulating vitamin D in these same 
subjects (45). Inverse HCC risk associations with higher circulating lysoPCs are 
consistent with other reports (10;15;46). The observed association with creatine may 
reflect decreased liver functionality and lower creatine synthesis in HCC 
development, although it has also been ascribed both antioxidant and oxidative 
properties (47). Our observation of an inverse association with DHEA-S is intriguing 
because androgen receptor activity, with which DHEA-S interacts, has been 
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implicated in HCC development (48;49) and the promotion of HCC by androgens has 
been put forward as one explanation for its higher incidence in men (50). On the 
other hand, liver cirrhosis has been linked to hormonal imbalances between 
estrogens and androgens resulting in a higher relative concentration of estrogens 
(50). Some animal data even suggest that DHEA-S may protect against development 
of liver lesions (51). Thus, our observations merit more detailed assessment of 
hormonal factors and circulating concentrations.  
In an earlier study based on NMR spectroscopy within the same subjects, we found a 
positive HCC risk association for the amino acid tyrosine (16). Similar observations 
have been made in a Korean prospective cohort (25) and the Alpha-Tocopherol, 
Beta-Carotene Cancer prevention cohort (ATBC) composed of Finnish male smokers 
(18). Our observations in the present study were similar for tyrosine along with HPLA, 
a tyrosine metabolite. Tyrosine is found in several foods (e.g. cheeses, which 
incidentally have also been associated with increased HCC risk in our data (52)) and 
is produced endogenously from phenylalanine. Tyrosine levels are known to be 
altered in liver disease (53) while HPLA has demonstrated carcinogenic activity after 
long term sub-cutaneous injection in mice (54), and its urinary levels have been 
observed to be elevated in breast cancer patients (55).  
Positive HCC risk associations were also observed for isatin, L,L-cyclo(leucylprolyl), 
N1-acetylspermidine and sphingosine – although, very little is known about any 
physiological roles for these compounds in HCC development. Isatin is a biologically 
active endogenous metabolite with antioxidant and antiviral effects (56) - properties 
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that may be considered as cancer protective rather than explanatory of our observed 
positive HCC risk association. However, isatin can also be derived from gut microbial 
metabolism (56), and we can speculate that its higher circulating concentrations in 
HCC cases may be due to leakage from the gut across a dysfunctional colonic 
barrier, something which we have previously observed in the same HCC cases (57). 
For its part, L,L-cyclo(leucyl-prolyl) has been associated with increased liver fat 
content in a German general population sample (58), possibly suggesting a link with 
fatty liver disease in some of our cases. There is sparse data on the possible roles of 
N1-acetylspermidine (a polyamine) and sphingosine (an aminodiol which can form 
ceramides, parent structures to sphingolipids) in HCC. The former may be affected 
by liver functionality (59) and its serum levels have been shown to be higher in liver 
cancer patients (60) whereas sphingosine has been observed to be elevated in 
chronic liver diseases, such as non-alcoholic fatty liver disease and chronic hepatitis 
C infection (61). Thus, alterations in circulating levels of these metabolites may be 
indicative of liver dysfunctionality and possibly early HCC development.   
Another interesting observation from our study is the positive HCC risk association of 
glycochenodeoxycholic acid and glycocholic acid – both of which are glycine 
conjugates of primary bile acids formed in the liver (62). Their circulating 
concentrations have been shown to be increased in various liver diseases, including 
HCC (10;15;25;46;63;64). In general, pro-inflammatory and carcinogenic properties 
have been ascribed to bile acids and as such they have a plausible role in HCC 
development (65). Perturbations in serum bile acid metabolism have been previously 
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observed in other settings, such as in largely hepatitis positive Chinese populations 
(66;67), and specifically for glycochenodeoxycholic acid and glycocholic acid in the 
ATBC cohort (18). The liver is central to bile acid metabolism, and hence 
perturbations in bile acid profiles may be amongst the earliest indicators of HCC 
development. A more detailed analysis of potential alterations in the profiles of 
various bile acids in the different phases of this disease would be of great interest.  
In our observations, the metabolite most strongly positively associated with HCC risk 
is 7-methylguanine, an indicator of exposure to methylating agents. It has previously 
been observed to be higher in the urine of smokers (68) and those with unhealthy 
lifestyle habits (69) – exposures which have also been associated with increased 
HCC risk in our cohort (34;70). Higher levels of this compound have also been 
associated with an increased risk of total mortality in a cohort of male smokers (71). It 
may thus be a metabolite related to smoking exposure, and so further study of its 
potential role in HCC development is warranted. 
Taken together, our findings relate to dietary and lifestyle exposures that may be 
potentially HCC promoting, as well as to liver dysfunctionality which is central to the 
development of HCC and other liver diseases.  
A major limitation of our study nested within a prospective cohort is the lack of 
information on the existence and severity of any other liver diseases leading up to 
HCC development. For example, information on existing liver cirrhosis would have 
been helpful in further characterizing our HCC cases between cirrhotic and non-
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cirrhotic pathways of HCC development. A related critique of our study design is the 
lack of a second control group composed of subjects with liver diseases. We do not 
have any access to relevant clinical information on liver diseases amongst our 
>520,000 cohort participants. However, such a control group would have allowed us 
to better understand transitions from existing liver pathologies towards early HCC. 
Although this is a reasonable assertion for studies designed to assess clinical 
surveillance for HCC in higher risk populations, it is less relevant to prospective 
cohorts geared towards exploring cancer etiology in the general population. 
Nevertheless, we have addressed these concerns by making multivariable statistical 
adjustments for main HCC risk factors in our study population. These adjustments 
did not meaningfully alter our findings, suggesting that different HCC etiologies – 
whether related mainly to chronic hepatitis infection, alcohol abuse, smoking or 
obesity – may have a large degree of overlap in terms of their metabolic 
consequences on the liver and hence transitions towards development of HCC. 
Patient cohorts comparing HCC cases to control subjects with liver disease provide 
vital insight towards risk stratification for HCC screening and identification of 
diagnostic biomarkers, they have to be distinguished from findings such as ours 
which are based on large-scale prospective cohort studies and which bring 
understanding of potential risk factors and metabolic perturbations in HCC 
development. Another limitation is our lack of information on any tumour staging 
criteria at diagnosis or treatments post-diagnosis. We did not consider survival and 
we cannot discount some degree of confounding by stage at diagnosis – but it must 
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be noted that biological samples in our cohort were collected at recruitment, pre-
diagnosis. In randomized clinical trials, allocation of exposure and prognostic factors 
would be random, but collection of data and biological samples in the cases is not 
likely to be pre-diagnostic. Studies with these different designs each provide crucial 
insight into the development of this lethal cancer, and should all be part of the 
evidence base for establishment of guidelines towards HCC prevention, as well as 
discovery of biomarkers for early diagnosis. We consider the fact that our HCC cases 
were derived from within an observational cohort with pre-diagnostically obtained 
biological samples and detailed confounder data as a major advantage that 
minimises recall and reverse causality biases adding another degree of robustness to 
our observations. At the same time, we acknowledge that our study design does not 
allow insight into transitions from existing liver pathologies towards HCC.  
Another important design advantage of this work is that we applied an agnostic 
metabolomics approach using high-resolution mass spectrometry with four 
complementary analytical configurations (72) enabling us to maximize the number of 
metabolites measured for a more complete assessment of metabolic profile changes 
between the HCC cases and their matched controls. We identified many metabolites 
with very high confidence, but we also observed a number which we could not 
identify despite our best efforts. We believe that the high number of metabolites 
observed to be associated with HCC risk, both identified and unknown, highlights the 
depth of metabolic perturbation in this disease. The magnitude of some of the risk 
associations for the unidentified metabolites, whether inverse or positive, shows that 
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we still have much to learn about the processes of HCC development. The 
unidentified metabolites provide considerable potential for discovery of additional 
novel exposure, diagnostic and prognostic biomarkers in other studies. Our findings 
on specific identified metabolites and metabolic pathways involved in HCC 
development may be followed up with experimental studies to more carefully query 
their functionality and mechanisms of action. Additionally, it would be of great interest 
to determine whether any of our observed metabolites may serve as early diagnostic 
markers. 
In summary, we show statistically significant associations between 46 identified 
metabolites, which could be either directly involved in HCC development or be the 
consequence of liver dysfunction caused by tumourigenesis in the liver. Our 
observations, based on pre-diagnostically collected blood samples, contribute 
towards a more in-depth understanding of HCC risk factors and underlying 
mechanisms of HCC development. They contribute to the evidence base that may be 
used towards public health guidelines for HCC prevention, but they should also be 
replicated in other prospective cohorts from different world regions with emphasis on 
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Table 1. Characteristics of Hepatocellular Cancer (HCC) cases and matched control 
subjects, nested within the EPIC cohort. 
Table 2. Associations with risk of Hepatocellular Carcinoma (HCC) development for 
Level 1* identified metabolites.  
Table 3. Associations with risk of Hepatocellular Carcinoma (HCC) development for 
Level 2* (33) identified metabolites. 
Table 4. Associations with risk of Hepatocellular Carcinoma (HCC) development for 
Level 3 identified and Level 4 unidentified metabolites*. 
 
Figure Titles and Legends 
Figure 1 Title: Flow chart of the selection procedures for metabolites and number of 
annotated compounds for each analytical configuration of the UHPLC-QTOF-MS 
system. 
Figure 1 Legend: A total of 114 separate compounds (i.e. confirmed molecules that 
consisted of one or more features) were identified from the four datasets. Of these 
114 separate compounds, 22 were also detected by more than at least one of the 
other three profiling methods, leaving a total of 92 unique compounds. Of these 92 
compounds, 46 were identified into 3 distinct categories: unambiguously identified 
using pure standards (Level 1; n=14), identified to a high level of confidence based 
on chemical features and characteristics (Level 2; n=23), and identified to a known 
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chemical class (Level 3; n=9). The remaining 46 compounds were not identified, i.e. 
unknown. 
1 After Benjamini-Hochberg correction for multiple testing, conditioned on matching 
factors: age at blood collection (±1 year), sex, study center, time of the day at blood 
collection (±3 hours), fasting status at blood collection (<3, 3-6,and >6 hours); among 
women, additionally by menopausal status (pre-, peri-, and postmenopausal), and 
hormone replacement therapy use at time of blood collection (yes/no).    
2 After Benjamini-Hochberg correction for multiple testing: matching factors + BMI 
(kg/m2, continuous), waist circumference (cm, continuous), physical activity (Met-
h/wk, continuous), alcohol intake at recruitment (g/d, continuous), lifetime alcohol 
intake pattern (categorical), smoking status (categorical) and attained education 
(categorical).  
Please see Tables 2 to 4 for additional details. 
Figure 2 Title: Principal component (PC) analyses based on metabolites associated 
with HCC risk for (1) the 46 metabolites associated with HCC risk and identified at 
Levels 1 to 3 33 and (2) the 14 metabolites associated with HCC risk and identified at 
Level 1 only, i.e. unambiguous identification using pure standards33. HCC cases are 
shown by green circles and matched controls by mauve triangles. 
Figure 2 Legend: (A) Score plots of PC analyses differentiating cases and controls, 
(B) plot of scores on PC1 versus follow-up time (all years, number of HCC case and 
matched control sets=129; and excluding cases with 4 or less years of follow-up, 
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number of HCC case and matched control sets=87) and (C) relative contributions of 
identified metabolites to PC1 and PC2. For A1, the proportion of variability is 29.86% 
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Novelty and Impact: 
Changes in liver function precede the development of hepatocellular carcinoma (HCC). Many of 
these changes can be detected in the blood, as can biomarkers related to lifestyle or 
environmental exposures that may affect HCC risk. In this study, based on a large, prospective 
observational cohort, the authors used high resolution mass spectrometry-based metabolomics to 
identify alterations in circulating levels of 92 metabolites associated with HCC risk, 14 of which 
could be annotated with high confidence and some of which were observed up to 10 years prior 
to diagnosis. These results offer insight into early metabolic perturbations and mechanisms 
leading to this deadly cancer. 
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TABLES
Table 1. Characteristics of Hepatocellular Cancer (HCC) cases and matched control 









Women (n, %) 41 31.8 41 31.8
Age at recruitment (years),  mean (SD) 60.0 7.3 60.1 7.4 0.717
BMI (kg/m2), mean (SD) 28.4 4.6 27.4 4.3 0.062
Waist circumference (cm), mean (SD) 97.5 14.0 93.0 12.3 0.002
Physical activity  (MET-h/week), mean (SD) 83.4 54.2 85.0 50.8 0.873
Dietary alcohol (g/day), mean (SD) 22.5 35.9 15.8 20.0 0.058
Education (n, %) None / primary 68 52.7 64 49.2 0.5945
Technical / 
professional
34 26.4 29 22.3
Secondary 6 4.7 10 7.8
University or higher 19 14.7 23 17.8
Alcohol intake pattern (n, %) Never drinkers 9 7.0 12 9.3 0.0018
Former drinkers 23 17.8 4 3.1
Drinkers only at 
recruitment 
7 5.4 8 6.2
Always drinkers 90 69.8 105 80.8
Smoking status (n, %) Never smokers 42 32.6 60 46.5 0.0124
Former smokers 40 31.0 42 32.3
Current smokers 46 35.7 26 20.0
Hepatitis B and/or C 
infection (n, %) **
Yes 33 25.6 4 3.1 <0.0001
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HCV (n, %) Yes 19 14.7 2 1.5 <0.0001
HBV (n, %) Yes 17 13.2 3 2.3 <0.0001
Self-reported diabetes status 
at baseline (n, %)
Yes 12 9.3 6 4.7 0.1426
Liver function score (n, %) ҂ 0 24 18.6 75 58.1 <0.0001
≥1 66 51.2 16 12.4
Missing values were not excluded from percentage calculations, thus the sum of percent 
values across sub-groups may not add up to 100%. 
Number of cases and controls with missing or unknown variable value: education 
(controls=3, HHCC=2), smoking status (controls=1, HCC=1), hepatitis infection status 
(controls=38, HC =38), diabetes status (self-reported, controls=13, HCC =11), liver function 
score (controls=38, HCC=38). The distribution of cases by country is as follows: 
Denmark=23, Germany=32, Greece=16, Italy=28, the Netherlands=4, Spain=11, United 
Kingdom=15. 
Categorical variables are presented as numbers and percentages. Continuous variables are 
presented as mean and standard deviation (SD).
* Paired t-test for continuous and Fisher’s exact test for categorical variables were used to 
calculate p-value.
** Hepatitis B and/or C seropositivity were detected using the ARCHITECT HBsAg and anti-
HCV chemiluminescent microparticle immunoassays (CMIAs; Abbott Diagnostics, France)
҂ Liver function biomarkers (ALT, AST, GGT, ALP, albumin, bilirurbin) were measured on the 
ARCHITECT c Systems™ (Abbott Diagnostics). A liver function score was computed as an 
indicator of possible underlying liver damage. The score ranges from 0 to 6 and is based on 
abnormal liver function tests (ALT>55 U/L, AST>34 U/L, GGT >64 U/L for men and > 36 U/L 
for women, ALP > 150 U/L, albumin < 34 g/L, total bilirubin > 20.5 μmol/L; values were 
provided by the laboratory). For each liver function biomarker, participants with abnormal 
values (as defined above) were assigned a score of 1. Possible liver impairment category 
was created for the score ≥1.
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Table 2. Associations with risk of Hepatocellular Carcinoma (HCC) development for Level 1* identified metabolites. 
Identified and Annotated Analytical Retention Absolute Multivariable Adjusted 3 





OR (95% CI) q-value
Retinol RP+ 269.2273 7.27 -1.30 0.27 (0.16 - 0.48) 0.00060
Dehydroepiandrosterone 
Sulfate**
HILIC- 367.1561 0.80 -2.13 0.35 (0.22 - 0.57) 0.00350
Glycerophosphocholine RP+ 280.0920 0.64 -1.47 0.44 (0.28 - 0.71) 0.01080
γ-carboxyethyl hydroxychroman RP+ 265.1428 5.31 -1.23 0.56 (0.39 - 0.81) 0.01970
Creatine RP+ 132.0771 0.66 -1.20 0.56 (0.37 - 0.83) 0.03410
N1-Acetylspermidine* * HILIC+ 188.1759 6.85 1.20 2.16 (1.38 - 3.37) 0.01370
Isatin RP+ 148.0393 3.35 1.39 2.56 (1.53 – 4.29) 0.01490
p-Hydroxyphenyllactic acid HILIC- 181.0494 2.24 1.47 2.63 (1.62 – 4.28) 0.02200
Tyrosine RP+ 182.0816 1.28 1.20 2.77 (1.58 - 4.83) 0.02030
Sphingosine RP+ 300.2902 6.06 1.36 2.79 (1.66 - 4.71) 0.00360
L,L-Cyclo(leucylprolyl) RP+ 211.1442 3.90 2.37 3.25 (1.91 - 5.53) 0.00080
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Glycochenodeoxycholic acid ** RP+ 450.3218 6.48 3.37 3.31 (1.99 - 5.51) 0.00050
Glycocholic acid ** RP+ 466.3164 6.21 3.92 4.07 (2.32 - 7.14) 0.00040
7-methylguanine HILIC+ 166.0729 2.53 1.31 6.78 (3.24 - 14.18) 0.00030
* features identified with high confidence and verified by a chemical standard
** indicates that a compound was detected by more than one method. The listed method is the one showing the greatest intensity for the particular 
compound. Dehydroepiandrosterone Sulfate was also detected by RP-; N1-Acetylspermidine was also detected by RP+; Glycochenodeoxycholic 
acid was also detected by HILIC+, RP-; Glycocholic acid was also detected by RP-; Benzylcarnitine was also detected by RP+. 
1 Level 1 identified compounds: retention time and MS/MS matches with an authentic chemical standard (33). Information for compounds identified 
at Level 2 (identified compounds with high confidence; no standard available/analysed but matching isotope pattern, MS/MS spectra, and other 
supporting evidence) is shown on Table 3. Information for compounds identified at Level 3 (compounds identified from a known chemical class) 
and Level 4 (unidentified compounds) are shown in Table 4. 
2 Absolute fold change between the median intensities of cases to their matched controls.
3 The ORs represent the risk of HCC per 1 standard deviation (SD) of logarithm transformed value. Multivariable adjusted: matching factors + body 
mass index (BMI, kg/m2, continuous), Waist circumference (cm, continuous), alcohol intake at recruitment (g/d, continuous), Physical activity (Met-
h week, continuous), categories of smoking status, alcohol intake pattern and education (for categories see Table 1). 
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Table 3. Associations with risk of Hepatocellular Carcinoma (HCC) development for Level 2* identified metabolites.
Identified and Annotated Analytical Retention Absolute Multivariable Adjusted 3 





OR (95% CI) q-value
LysoPC(17:0) ** HILIC+ 510.3554 2.42 -1.64 0.21 (0.11 - 0.40) 0.00030
LysoPC(15:0) ** HILIC+ 482.3251 2.60 -1.54 0.23 (0.12 - 0.42) 0.00030
LysoPC(20:5) ** HILIC+ 564.3104 2.38 -1.52 0.23 (0.12 - 0.46) 0.00030
LysoPC(16:0) ** RP+* 991.6772 7.03 -1.26 0.28 (0.16 - 0.49) 0.00060
LysoPC(20:4) ** HILIC+ 544.3407 2.33 -1.40 0.31 (0.19 - 0.51) 0.00030
LysoPC(P-16:0) ** HILIC+ 480.3460 2.12 -1.25 0.33 (0.19 - 0.55) 0.00030
LysoPC(22:5) HILIC+ 570.3539 2.30 -1.33 0.33 (0.20 - 0.54) 0.00030
PC(38:6) RP+ 806.5690 8.51 -1.29 0.36 (0.21 - 0.61) 0.00460
LysoPC(22:6) ** HILIC+ 568.3399 2.28 -1.41 0.37 (0.23 - 0.58) 0.00030
LysoPC(18:2) ** HILIC+ 520.3418 2.46 -1.31 0.40 (0.26 - 0.64) 0.00030
LysoPC(18:0) ** HILIC+ 524.3712 2.34 -1.25 0.41 (0.26 - 0.65) 0.00250
C5 acylcarnitine HILIC+ 246.1703 3.17 -1.22 0.46 (0.29 - 0.73) 0.01770
DG(18:2/18:2/0:0) RP+ 639.4946 9.54 -1.39 0.47 (0.31 - 0.72) 0.00950
LysoPC(14:0) ** HILIC+ 468.3088 2.70 -1.26 0.48 (0.31 - 0.72) 0.00900
LysoPC(17:1) HILIC+ 508.3406 2.46 -1.27 0.48 (0.31 - 0.75) 0.01530
LysoPC (18:1) HILIC+ 522.3570 2.38 -1.24 0.52 (0.34 - 0.78) 0.02450
LysoPC(20:3) ** RP+ 546.3548 7.04 -1.21 0.56 (0.39 - 0.80) 0.01790
DG(18:1/18:2/0:0) RP+ 641.5106 10.10 -1.27 0.58 (0.40 - 0.85) 0.04060
PC(16:1/16:1/0:0) HILIC+ 730.5398 1.17 1.39 1.79 (1.22 - 2.64) 0.03570
Bilirubin isomer 2 RP+ 585.2687 4.34 1.26 1.89 (1.20 - 2.97) 0.04510
Bilirubin isomer 1 RP+ 585.2696 5.13 1.27 1.94 (1.22 - 3.06) 0.03850
PC(16:1/16:0/0:0) ** HILIC+ 732.5552 1.16 1.54 2.01 (1.33 - 3.03) 0.01410
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Benzoylcarnitine ** HILIC+ 266.1392 3.36 1.46 2.74 (1.69 - 4.42) 0.00030
 features identified with high confidence
** indicates that a compound was detected by more than one method. The listed method is the one showing the greatest intensity for the particular 
compound. LysoPC(17:0) was also detected by RP+/-; LysoPC(15:0) also by RP+; LysoPC(20:5) also by HILIC-, RP+/-; LysoPC(16:0) also by 
HILIC-; LysoPC(20:4) also by HILIC-, RP+/-; LysoPC(P-16:0) also by RP+; LysoPC(22:6) also by RP+/-; LysoPC(18:2) also by RP+, HILIC-; 
LysoPC(18:0) also by RP+, HILIC-; LysoPC(14:0) also by RP+; LysoPC(20:3) also by HILIC-; PC(16:1/16:0/0:0) also by RP+; Benzoylcarnitine also 
by RP+.
1 Level 1 identified compounds: retention time and MS/MS matches with an authentic chemical standard (Table 2); Level 2 (identified compounds 
with high confidence): no standard available/analysed but matching isotope pattern, MS/MS spectra, and other supporting evidence (33). 
Information for compounds identified at Level 3 (compounds identified from a known chemical class) and Level 4 (unidentified compounds) are 
shown in Table 4. 
2 Absolute fold changes between the median intensities of cases to their matched controls.
3 The OR represents the risk of HCC per 1 SD of logarithm transformed value.  Multivariable adjusted: matching factors + body mass index (BMI, 
kg/m2, continuous), Waist circumference (cm, continuous), alcohol intake at recruitment (g/d, continuous), Physical activity (Met-h wk, continuous), 
categories of smoking status, alcohol intake pattern and education (for categories see Table 1). 
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Table 4. Associations with risk of Hepatocellular Carcinoma (HCC) development for Level 3 identified and Level 4 unidentified 
metabolites*.
Level of Chemical Class of Analytical Retention Absolute Multivariable Adjusted 3 
Identification 1 Compound Method m/z Time (min)
Fold 
Change2
OR (95% CI) q-value
3 C19H30O2-sulfate (Steroid-S) HILIC- 369.1710 0.81 -3.79 0.20 (0.11 - 0.39) 0.00080
3 Leucyl-Valine or isomer RP+ 231.1703 2.28 -2.32 0.28 (0.16 - 0.49) 0.00050
3 LysoPC/PC HILIC+ 633.3975 2.22 -1.67 0.35 (0.21 - 0.57) 0.00030
3 LysoPC(18:2) isomer HILIC- 564.3263 2.09 -1.30 0.39 (0.24 - 0.63) 0.01000
3 LysoPC/PC HILIC+ 609.3992 2.24 -1.38 0.41 (0.26 - 0.63) 0.00030
3 Tryptophyl-phenylalanine RP+ 352.1663 3.61 -1.30 0.48 (0.30 - 0.76) 0.01750
3 L,L-Cyclo(isoleucylprolyl) RP+ 211.1443 3.79 1.45 1.86 (1.21 - 2.84) 0.03600
3 C19H30O3-sulfate (OH-Steroid-S) RP- 385.1661 5.05 1.29 2.30 (1.46 - 3.61) 0.03050
3 C19H28O3-sulfate (OH-DHEA-S)** RP- 383.1505 5.48 1.87 2.59 (1.67 - 4.01) 0.00410
4 Unknown RP+ 551.3114 6.94 -1.32 0.22 (0.11 - 0.42) 0.00060
4 Unknown RP+ 571.2988 6.93 -1.30 0.24 (0.13 - 0.43) 0.00040
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Level of Chemical Class of Analytical Retention Absolute Multivariable Adjusted 3 
Identification 1 Compound Method m/z Time (min)
Fold 
Change2
OR (95% CI) q-value
4 Unknown RP+ 794.9647 6.96 -1.35 0.31 (0.18 - 0.54) 0.00160
4 Unknown RP+ 268.1413 0.88 -1.34 0.33 (0.18 - 0.62) 0.00950
4 Unknown RP+ 239.0915 4.29 -1.76 0.35 (0.19 - 0.63) 0.00910
4 Unknown RP+ 543.3458 7.28 -1.27 0.39 (0.24 - 0.62) 0.00330
4 Unknown RP+ 203.1392 0.88 -1.52 0.39 (0.23 - 0.68) 0.01160
4 Unknown RP+ 169.9858 0.62 -1.34 0.41(0.23 - 0.71) 0.01680
4 Unknown RP+ 203.1391 1.65 -1.46 0.42 (0.24 - 0.72) 0.01850
4 Unknown RP+ 548.3020 6.95 -1.29 0.42 (0.27 - 0.66) 0.00480
4 Unknown RP+ 500.2774 6.81 -1.25 0.44 (0.27 - 0.70) 0.00940
4 Unknown RP+ 257.2267 6.91 -1.49 0.45 (0.29 - 0.70) 0.00770
4 Unknown HILIC+ 116.1064 1.69 -1.38 0.46 (0.30 - 0.69) 0.00390
4 Unknown RP+ 423.7686 8.82 -1.30 0.46 (0.30 - 0.71) 0.00850
4 Unknown RP- 228.9786 3.40 -1.31 0.47 (0.31 - 0.72) 0.03380
4 Unknown RP+ 536.3023 6.97 -1.29 0.47 (0.30 - 0.73) 0.01090
4 Unknown RP+ 283.1552 6.21 -1.36 0.48 (0.30 - 0.75) 0.01680
4 Unknown RP+ 541.3301 7.10 -1.20 0.48 (0.30 - 0.76) 0.01880
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9
Level of Chemical Class of Analytical Retention Absolute Multivariable Adjusted 3 
Identification 1 Compound Method m/z Time (min)
Fold 
Change2
OR (95% CI) q-value
4 Unknown RP+ 401.3414 7.72 -1.21 0.53 (0.35 - 0.80) 0.02470
4 Unknown HILIC+ 183.1120 1.31 -1.30 0.54 (0.37 - 0.80) 0.02630
4 Unknown RP+ 118.0498 0.86 -1.21 0.55 (0.36 - 0.82) 0.02950
4 Unknown RP+ 254.0234 4.23 1.51 1.62 (1.17 - 2.24) 0.03190
4 Unknown RP+ 330.2464 5.98 1.22 1.78 (1.22 - 2.61) 0.02690
4 Unknown RP+ 243.1954 6.71 1.40 1.81 (1.24 - 2.63) 0.02020
4 Unknown RP+ 281.2489 6.81 1.42 1.82 (1.24 - 2.67) 0.02250
4 Unknown RP+ 175.0264 1.66 1.57 1.88 (1.23 - 2.87) 0.03130
4 Unknown HILIC+ 120.0657 1.83 1.22 1.97 (1.23 - 3.16) 0.04940
4 Unknown RP+ 241.1543 3.78 1.30 2.00 (1.30 - 3.09) 0.01880
4 Unknown RP+ 104.0710 0.64 1.27 2.05 (1.37 - 3.06) 0.00910
4 Unknown RP+ 202.1187 0.87 1.34 2.06 (1.30 - 3.25) 0.02070
4 Unknown HILIC- 308.0712 2.34 1.40 2.17 (1.42 - 3.31) 0.02200
4 Unknown RP+ 203.1393 0.73 1.27 2.20 (1.41 - 3.45) 0.00950
4 Unknown RP+ 129.0649 1.59 1.23 2.26 (1.42 - 3.59) 0.00990
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10
Level of Chemical Class of Analytical Retention Absolute Multivariable Adjusted 3 
Identification 1 Compound Method m/z Time (min)
Fold 
Change2
OR (95% CI) q-value
4 Unknown RP+ 129.0661 0.65 1.28 2.34 (1.45 - 3.74) 0.00840
4 Unknown RP- 71.0501 2.78 1.23 2.35 (1.44 - 3.82) 0.03690
4 Unknown RP- 475.3034 6.86 1.41 2.37 (1.57 - 3.60) 0.00680
4 Unknown RP+ 163.0752 2.09 1.20 2.38 (1.46 - 3.88) 0.00890
4 Unknown RP+ 203.0214 2.78 1.20 2.46 (1.43 - 4.24) 0.01470
4 Unknown HILIC+ 203.1395 5.32 1.37 2.51 (1.55 - 4.05) 0.00390
4 Unknown RP- 146.0448 0.65 1.34 2.56 (1.53 - 4.29) 0.03120
4 Unknown RP+ 619.5268 7.00 1.49 2.57 (1.61 - 4.13) 0.00280
4 Unknown RP+ 182.0814 0.87 1.25 2.63 (1.62 - 4.28) 0.00290
4 Unknown HILIC+ 126.0662 3.35 1.20 2.67 (1.59 - 4.48) 0.00390
4 Unknown RP+ 431.3169 6.85 1.38 2.80 (1.76 - 4.47) 0.00090
4 Unknown RP+ 389.2650 6.37 1.77 3.22 (1.77 - 5.85) 0.00380
4 Unknown RP+ 614.5721 7.00 1.25 3.75 (1.99 - 7.05) 0.00190
* features that are identified at the level of the chemical class (Level 3) or unknown (Level 4) (33).
** indicates that a compound was detected by more than one method, also listed. Data are provided only for the method that showed the greatest intensity for 
the particular compound: C19H28O3-sulfate (OH-DHEA-S) was also detected by HILIC-ve. 
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11
1 Compounds identified at Level 3 (compound from a known chemical class) and Level 4 (unknown compounds) are shown here (33). Information for 
compounds identified at Level 1 (retention time and MS/MS matches with an authentic chemical standard) and Level 2 (no standard available/analysed but 
matching isotope pattern, MS/MS spectra, and other supporting evidence) are shown in Tables 2 and 3, respectively. 
2 Absolute fold change between the median intensities of cases to their matched controls.
3 The OR represent the risk of HCC per 1 SD of logarithm transformed value. Multivariable adjusted: matching factors + body mass index (BMI, kg/m2, 
continuous), Waist circumference (cm, continuous), alcohol intake at recruitment (g/d, continuous), Physical activity (Met-h wk, continuous), categories of 
smoking status, alcohol intake pattern and education (for categories see Table 1).
LysoPC=lysophosphatidylcholine; Unknown = not identifiable; identity or chemical class not ascertainable.
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Figure 1: 
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crude models 
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adjusted models 
 
Features with median fold change 
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Number of unique compounds from 
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Figure 2. Principal component (PC) analyses based on metabolites associated with HCC 
risk for (1) the 46 metabolites associated with HCC risk and identified at Levels 1 to 3 33 and 
(2) the 14 metabolites associated with HCC risk and identified at Level 1 only, i.e. 
unambiguous identification using pure standards33. HCC cases are shown by green circles 
and matched controls by mauve triangles. 
A. Score plots of PC analyses differentiating cases and controls 
B.  Plot of scores on PC1 versus follow-up time 
 
PC 1 (29.86%) vs PC2 (11.12%) 
(1) 46 metabolites identified at Levels 1-3  
PC 1 (29.18%) vs PC2 (11.16%) 
(2) 14 metabolites identified at Level 1  
(1) 46 metabolites identified annotated at 
Levels 1-3  
(2) 14 metabolites identified at Level 1  
Excluding cases with 4 or less years of follow-
up, Levels 1-3 
Excluding cases with 4 or less years of follow-
up, Level 1 
129 cases 
129 matched controls 
129 cases 
129 matched controls 
87 cases 
87 matched controls 
87 cases 
87 matched controls 
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(1) 46 metabolites identified at Levels 1-3  
(2) 14 metabolites identified at Level 1  
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